These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30446753)

  • 1. LAG-3: a very singular immune checkpoint.
    Lui Y; Davis SJ
    Nat Immunol; 2018 Dec; 19(12):1278-1279. PubMed ID: 30446753
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer].
    Wei T; Zhang J; Wu Y; Zhang D; Lu L; Shen Q
    Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):424-9. PubMed ID: 25241783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
    Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
    Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequencies of PD-1- and PD-L1- positive T CD3
    Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
    Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
    Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.
    Samimi S; Benoit B; Evans K; Wherry EJ; Showe L; Wysocka M; Rook AH
    Arch Dermatol; 2010 Dec; 146(12):1382-8. PubMed ID: 20713771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer.
    Rutkowski J; Cyman M; Ślebioda T; Bemben K; Rutkowska A; Gruchała M; Kmieć Z; Pliszka A; Zaucha R
    Cell Immunol; 2017 Dec; 322():26-33. PubMed ID: 28939130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.
    Pettersen FO; Taskén K; Kvale D
    Clin Exp Immunol; 2010 Aug; 161(2):315-23. PubMed ID: 20491784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment.
    Grabmeier-Pfistershammer K; Steinberger P; Rieger A; Leitner J; Kohrgruber N
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):118-24. PubMed ID: 20980914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans.
    Eller MA; Blom KG; Gonzalez VD; Eller LA; Naluyima P; Laeyendecker O; Quinn TC; Kiwanuka N; Serwadda D; Sewankambo NK; Tasseneetrithep B; Wawer MJ; Gray RH; Marovich MA; Michael NL; de Souza MS; Wabwire-Mangen F; Robb ML; Currier JR; Sandberg JK
    PLoS One; 2011 Apr; 6(4):e18779. PubMed ID: 21526194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.
    Ikematsu Y; Tanaka K; Yanagihara T; Liu R; Inoue H; Yoneshima Y; Ota K; Iwama E; Takata S; Hata K; Takahata Y; Wataya H; Nakanishi Y; Okamoto I
    Lung Cancer; 2019 Dec; 138():58-64. PubMed ID: 31639551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint dysfunction in large and medium vessel vasculitis.
    Watanabe R; Zhang H; Berry G; Goronzy JJ; Weyand CM
    Am J Physiol Heart Circ Physiol; 2017 May; 312(5):H1052-H1059. PubMed ID: 28314758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
    Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
    Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction.
    D'Souza M; Fontenot AP; Mack DG; Lozupone C; Dillon S; Meditz A; Wilson CC; Connick E; Palmer BE
    J Immunol; 2007 Aug; 179(3):1979-87. PubMed ID: 17641065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.
    Shimauchi T; Kabashima K; Nakashima D; Sugita K; Yamada Y; Hino R; Tokura Y
    Int J Cancer; 2007 Dec; 121(12):2585-90. PubMed ID: 17721918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.